Memorial Sloan Kettering Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
Phase 1
Completed
- Conditions
- Neuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00037011
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Biological: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccineBiological: QS21
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00030823
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
Not Applicable
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Drug: chemotherapyProcedure: computed tomographyProcedure: conventional surgeryProcedure: neoadjuvant therapyProcedure: positron emission tomographyProcedure: radionuclide imagingRadiation: fludeoxyglucose F 18Radiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 149
- Registration Number
- NCT00004891
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal CancerMetastatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00008294
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy
Phase 1
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006044
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
Phase 2
Completed
- Conditions
- Liver Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00040898
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004245
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase 2
Completed
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00016159
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
Phase 2
Completed
- Conditions
- Melanoma (Skin)Sarcoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00004250
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2
Completed
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Biological: alemtuzumabProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00027560
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath